Original Article

Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis


Background: We aimed to investigate the expressions of miR-21 and miR-210 in the breast cancer tissue and their correlation with clinicopathological features and prognosis.

Methods: A retrospective analysis was performed on 68 patients with breast cancer treated surgically in Wuhan General Hospital of Guangzhou Military in 2014-2015. The breast cancer tissue and the adjacent normal tissue were collected from the patients. Quantitative real-time PCR (qRT-PCR) was used to detect the expression levels of miR-21 and miR-210 in the breast cancer and adjacent normal tissues.

Results: According to qRT-PCR, the expression levels of miR-210 and miR-21 in the breast cancer tissue were significantly higher than those in the adjacent normal tissue (P<0.05), which were significantly correlated with lymph node metastasis, clinical staging and differentiation of patients (P<0.05). miR-21 and miR-210 were significantly positive correlated in both breast cancer tissues and adjacent normal tissues (r=0.7014, 0.7502, P<0.001). The survival rate in the miR-210 high expression group was significantly lower than that in the miR-210 low expression group (P<0.05), whereas there was no significant difference between the miR-21 high and low expression groups.

Conclusion: miR-21 and miR-210 are highly expressed in the breast cancer tissue and significantly correlated with lymph node metastasis, clinical staging and differentiation. miR-210, the up-regulated expression of which is related to the poor prognosis of patients with breast cancer, may be a potential prognostic indicator for breast cancer, which can be used to judge the prognosis.

1. Wang X, Zhu J (2018). Mir-1307 regulates cisplatin resistance by targetingMdm4 in breast cancer expressing wild type P53. Thorac Cancer, 9: 676-683.
2. Perou CM, Sørlie T, Eisen MB et al (2000). Molecular portraits of human breast tu-mours. Nature, 406: 747-752.
3. Zindy F, Kawauchi D, Lee Y et al (2014). Role of the miR-17∼92 cluster family in cerebellar and medulloblastoma devel-opment. Biol Open, 3: 597-605.
4. Murphy BL, Obad S, Bihannic L et al (2013). Silencing of the miR-17~92 clus-ter family inhibits medulloblastoma pro-gression. Cancer Res, 73: 7068-7078.
5. Qiu X, Dou Y (2017). miR-1307 promotes the proliferation of prostate cancer by targeting FOXO3A. Biomed Pharmacother, 88: 430-435.
6. Iorio MV, Ferracin M, Liu CG et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65: 7065-7070.
7. Potter JW, Jones KB, Barrott JJ (2018). Sar-coma-The standard-bearer in cancer dis-covery. Crit Rev Oncol Hematol, 126: 1-5.
8. Mirzaei HR, Sahebkar A, Mohammadi M et al (2016). Circulating microRNAs in Hepatocellular Carcinoma:Potential Diag-nostic and Prognostic Biomarkers. Curr Pharm Des, 22: 5257-5269.
9. Sekar D, Krishnan R, Thirugnanasam-bantham K, Rajasekaran B, Islam VI, Sekar P (2016). Significance of microRNA 21 in gastric cancer. Clin Res Hepatol Gas-troenterol, 40: 538-545.
10. Bai H, Cao D, Yang J, Li M, Zhang Z, Shen K (2016). Genetic and epigenetic hetero-geneity of epithelial ovarian cancer and the clinical implications for moleculartar-geted therapy. J Cell Mol Med, 20: 581-593.
11. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY (2007). miR-21-mediated tumor growth. Oncogene, 26: 2799-2803.
12. Lee JA, Lee HY, Lee ES, Kim I, Bae JW (2011). Prognostic implications of mi-croRNA-21 overexpression in invasive ductal carcinomas of the breast. J Breast Cancer, 14: 269–275.
13. Guo W, Lian S, Zhen L et al (2018). The fa-vored mechanism for coping with acute cold stress:upregulation of miR-210 in rats. Cell Physiol Biochem, 46: 2090-2102.
14. Chan SY, Loscalzo J (2010). MicroRNA-210: A unique and pleiotropic hypoxamir. Cell Cycle, 9: 1072-1083.
15. Król M, Motyl T (2014). Exploiting cancer genomics in pet animals to gain ad-vantage for personalized medicine deci-sions. J Appl Genet, 55: 337-341.
16. Lakhtakia R, Chinoy RF (2014). A Brief His-tory of Breast Cancer: Part II - Evolution of surgical pathology. Sultan Qaboos Univ Med J, 14: e319-22.
17. Dawson SJ, Rueda OM, Aparicio S, Caldas C (2013). A new genome-driven integrat-ed classification of breast cancer and its implications. EMBO J, 35: 617-628.
18. Bedard PL, Hansen AR, Ratain MJ, Siu LL (2013). Tumour heterogeneity in the clin-ic. Nature, 501: 355-364.
19. Ali R, Samman N, Al Zahrani H et al (2017). Isolation and characterization of a new naturally immortalized human breast-carcinoma cell line, KAIMRC1. BMC Can-cer, 17: 803.
20. Hojny J, Zemankova P, Lhota F et al (2017). Multiplex PCR and NGS-based identifi-cation of mRNA splicing variants: Analy-sis of BRCA1 splicing pattern as a model. Gene, 637: 41-49.
21. Listinsky JJ, Siegal GP, Listinsky CM (2011). The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res, 3: 292-322.
22. Izzotti A, Carozzo S, Pulliero A, Zhabayeva D, Ravetti JL, Bersimbaev R (2016). Ex-tracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and pre-vention. Am J Cancer Res, 6: 1461-1493.
23. Tang Y, Zhou X, Ji J et al (2015). High ex-pression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis. Int J Biol Markers, 30: e347-358.
24. Galasso M, Sandhu SK, Volinia S (2012). MicroRNA expression signatures in solid malignancies. Cancer J, 18: 238-243.
25. Kumar AS, Rayala SK, Venkatraman G (2018). Targeting IGF1R pathway in can-cer with microRNAs: How close are we? RNA Biol, 15: 320-326.
26. Lu M, Zhan X (2018). The crucial role of multiomic approach in cancer research and clinically relevant outcomes. EPMA J, 9: 77-102.
27. Yadav P, Mirza M, Nandi K et al (2016). Se-rum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients. Tumour Biol, 37: 1-8.
28. Fang Q, Qu AL, Zhang X et al (2015). Ex-pression and clinical significance of miR-210 in the serum of patients with colorec-tal cancer. Journal of Shandong Universi-ty (Health Sciences) 53: 77-81.
29. Toyama T, Kondo N, Endo Y et al (2012). High expression of microRNA-210 is an independent factor indicating a poor prognosis in Japanese triple-negative breast cancer patients. Jpn J Clin Oncol, 472: 256-263.
30. Jinling W, Sijing S, Jie Z, Guinian W (2016). Prognostic value of circulating mi-croRNA-21 for breast cancer: a systemat-ic review and meta-analysis. Artif Cells Nanomed Biotechnol, 45: 1-6.
IssueVol 49 No 1 (2020) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v49i1.3048
miR-21 miR-210 Breast cancer Prognosis Clinicopathology

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
WU X. Expressions of miR-21 and miR-210 in Breast Cancer and Their Predictive Values for Prognosis. Iran J Public Health. 2020;49(1):21-29.